Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

Science Translational Medicine

Volumn 6, Issue 261, 2014, Pages

  Yu, Y Joy ^a   Atwal, Jasvinder K ^a   Zhang, Yin ^a   Tong, Raymond K ^a   Wildsmith, Kristin R ^a   Tan, Christine ^a   Bien Ly, Nga ^a   Hersom, Maria ^a   Maloney, Janice A ^a   Meilandt, William J ^a   Bumbaca, Daniela ^a   Gadkar, Kapil ^a   Hoyte, Kwame ^a   Luk, Wilman ^a   Lu, Yanmei ^a   Ernst, James A ^a   Scearce Levie, Kimberly ^a   Couch, Jessica A ^a   Dennis, Mark S ^a   Watts, Ryan J ^a  

^a GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; BETA SECRETASE; BETA SECRETASE 1; BISPECIFIC ANTIBODY; TRANSFERRIN RECEPTOR; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; CD71 ANTIGEN; LEUKOCYTE ANTIGEN; PEPTIDE FRAGMENT; SECRETASE;

ANIMAL EXPERIMENT; ANTIBODY AFFINITY; ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; BLOOD BRAIN BARRIER; CELL LOSS; CEREBROSPINAL FLUID; CONTROLLED STUDY; DRUG SAFETY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PROTEIN FUNCTION; PROTEIN TARGETING; RETICULOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BLOOD; C57BL MOUSE; CAPILLARY PERMEABILITY; CHO CELL LINE; CRICETULUS; CROSS REACTION; DOWN REGULATION; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MACACA FASCICULARIS; METABOLISM; TRANSGENIC MOUSE; TRANSPORT AT THE CELLULAR LEVEL;

ADMINISTRATION, INTRAVENOUS; AMYLOID BETA-PEPTIDES; AMYLOID PRECURSOR PROTEIN SECRETASES; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODY SPECIFICITY; ANTIGENS, CD; ASPARTIC ACID ENDOPEPTIDASES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; CAPILLARY PERMEABILITY; CHO CELLS; CRICETULUS; CROSS REACTIONS; DOWN-REGULATION; HEK293 CELLS; HUMANS; MACACA FASCICULARIS; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; RECEPTORS, TRANSFERRIN; TRANSFECTION;

EID: 84908884134     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3009835     Document Type: Article

References (16)

1. A. R. Jones, E. V. Shusta, Blood-brain barrier transport of therapeutics via receptor-mediation. Pharm. Res. 24, 1759-1771 (2007).
2. J. Lichota, T. Skjørringe, L. B. Thomsen, T. Moos, Macromolecular drug transport into the brain using targeted therapy. J. Neurochem. 113, 1-13 (2010).
3. Y. J. Yu, R. J. Watts, Developing therapeutic antibodies for neurodegenerative disease. Neurotherapeutics 10, 459-472 (2013).
4. R. D. Bell, M. D. Ehlers, Breaching the blood-brain barrier for drug delivery. Neuron 81, 1-3 (2014).
5. R. J. Watts, M. S. Dennis, Bispecific antibodies for delivery into the brain. Curr. Opin. Chem. Biol. 17, 393-399 (2013).
6. Y. J. Yu, Y. Zhang, M. Kenrick, K. Hoyte, W. Luk, Y. Lu, J. Atwal, J. M. Elliott, S. Prabhu, R. J. Watts, M. S. Dennis, Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3, 84ra44 (2011).
7. J. A. Couch, Y. J. Yu, Y. Zhang, J. M. Tarrant, R. N. Fuji, W. J. Meilandt, H. Solanoy, R. K. Tong, K. Hoyte, W. Luk, Y. Lu, K. Gadkar, S. Prabhu, B. A. Ordonia, Q. Nguyen, Y. Lin, Z. Lin, M. Balazs, K. Scearce-Levie, J. A. Ernst, M. S. Dennis, R. J. Watts, Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier. Sci. Transl. Med. 5, 183ra57 (2013).
8. J. Niewoehner, B. Bohrmann, L. Collin, E. Urich, H. Sade, P. Maier, P. Rueger, J. O. Stracke, W. Lau, A. C. Tissot, H. Loetscher, A. Ghosh, P. O. Freskgård, Increased brain penetration and potency of a therapeutic antibody using a monovalent molecular shuttle. Neuron 81, 49-60 (2014).
9. J. B. Ridgway, L. G. Presta, P. Carter, 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng. 9, 617-621 (1996).
10. R. Yan, R. Vassar, Targeting the b secretase BACE1 for Alzheimer's disease therapy. Lancet Neurol. 13, 319-329 (2014).
11. J. K. Atwal, Y. Chen, C. Chiu, D. L. Mortensen, W. J. Meilandt, Y. Liu, C. E. Heise, K. Hoyte, W. Luk, Y. Lu, K. Peng, P. Wu, L. Rouge, Y. Zhang, R. A. Lazarus, K. Scearce-Levie, W. Wang, Y. Wu, M. Tessier-Lavigne, R. J. Watts, A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo. Sci. Transl. Med. 3, 84ra43 (2011).
12. L. Zhou, L. Chávez-Gutiérrez, K. Bockstael, R. Sannerud, W. Annaert, P. C. May, E. Karran, B. De Strooper, Inhibition of b-secretase in vivo via antibody binding to unique loops (D and F) of BACE1. J. Biol. Chem. 286, 8677-8687 (2011).
13. N. Bien-Ly, Y. J. Yu, D. Bumbaca, J. Elstrott, C. A. Boswell, Y. Zhang, W. Luk, Y. Lu, M. S. Dennis, R. M. Weimer, I. Chung, R. J. Watts, Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants. J. Exp. Med. 211, 233-244 (2014).
14. Y. Lu, D. Riddell, E. Hajos-Korcsok, K. Bales, K. M. Wood, C. E. Nolan, A. E. Robshaw, L. Zhang, L. Leung, S. L. Becker, E. Tseng, J. Barricklow, E. H. Miller, S. Osgood, B. T. O'Neill, M. A. Brodney, D. S. Johnson, M. Pettersson, Cerebrospinal fluid amyloid-β (Aβ) as an effect biomarker for brain Ab lowering verified by quantitative preclinical analyses. J. Pharmacol. Exp. Ther. 342, 366-375 (2012).
15. S. Warming, R. A. Rachel, N. A. Jenkins, N. G. Copeland, Zfp423 is required for normal cerebellar development. Mol. Cell. Biol. 26, 6913-6922 (2006).
16. P. Liu, N. A. Jenkins, N. G. Copeland, A highly efficient recombineering-based method for generating conditional knockout mutations. Genome Res. 13, 476-484 (2003).